TNF inhibitor

RheumNow Podcast – Pounds of Prevention (3.5.2021)

Save

Dr. Jack Cush reviews and discusses nearly a dozen news reports and journal articles from the past week on RheumNow.com.

Measureable Benefits to Treat-to-Target Management in RA

Save

Desai and colleagues have published that when a learning collaborative group focused on a treat‐to‐target approach was compared to usual care, a modest but significant impact on implementation, treatment changes and patient outcomes in RA patients managed with a treat‐to‐target approach was seen

Weekly Semaglutide for Weight Loss in Adults

Save

NEJM has reported the results of a trial showing semaglutide once weekly plus lifestyle intervention was associated with sustained, weight loss in overweight or obese adults; such that nearly one-third lost over 20% of their body weight.

Semaglutide, a once weekly glucagon-like

ACR Promotes New COVID-19 Vaccine Clinical Guidance for Rheumatic Patients

Save

The American College of Rheumatology has published a draft guidance on the use of COVID-19 vaccination in rheumatic disease and musculoskeletal disease patients, based on the efforts of the North American Task force. The document provides guidance to rheumatology providers on the use of the

Synovial Tissue Signature Guiding Targeted IL-6 Therapy in RA

Save

RNA sequencing and classification of RA subsets has proven useful. RNA sequencing-based stratification of RA synovial tissue showed stronger associations with clinical responses compared with histopathological classification. Additionally, for patients with low or absent B-cell lineage

Comorbidity and Drugs Drive COVID-19 Severity and Survival in Rheumatic Disease

Save

While comorbidities are associated with severe COVID-19 infection, it appears they also influence severity and survival in rheumatic disease (RMD), according to a a French cohort study,

Analysis of a French RMD cohort with SARS-CoV-2 infection analyzed the effect of inflammatory

RheumNow Podcast – Tofacitinib Safety Concerns (2.5.2021)

Save

Dr. Jack Cush reviews and discusses the news and journal reports from the past week on RheumNow.com.

Cardiac and Cancer Signals Tofacitinib Safety Alert from FDA

Save

The FDA has notified healthcare professionals of a safety alert concerning tofacitinib (Xeljanz), noting that preliminary results from a long-term safety clinical trial show an increased risk of serious heart-related problems and cancer with tofacitinib (compared to adalimumab) when given to

Health Canada Approves Subcutaneous Infliximab Biosimilar

Save

The infliximab biosimilar CT-P13, developed by Celltrion and marketed as Remsima has been approved by HealthCanad for subcutaneous (SC) use in all the indications for infliximab. Last year the EMA approved the subcutaneous use of Celltrions Remsima SC;

Vagal Nerve Stimulation in Rheumatoid Arthritis

Save

Lancet Rheumatology has reported the results of a proof of concept trial, wherein vagal nerve stimulation was shown to ameliorate RA disease activity. The intervention involved non-invasive stimulation of the auricular branch of the vagus nerve using a wearable vagus nerve stimulation device for

RheumNow Podcast – Rheumatology Burnout (1.29.2021)

Save

Dr. Jack Cush reviews this past week's journal articles and news features on RheumNow.com. Colchicine, vaccine rollout, risk of RA in endometriosis patients, tREACH trial, lupus nephritis news, rheumatology burnout and more.

Calculating Serious Infection Risk in IMID Patients

Save

Predictive modeling of data derived from the DANBIO registry (of treated IMID patients) revealed a 4 fold increased risk of serious infection (SIE) in those starting biologic DMARD (bDMARD) treatment. From this large dataset, researchers developed a simple prediction model to estimate future

JAK Inhibitor Misses Endpoint in Safety Study. Now What?

Save

Pfizer announced results Wednesday from its FDA-mandated postmarketing safety study of tofacitinib (Xeljanz), and they don't bode well for the drug and possibly others in its class.

Compared with patients taking tumor necrosis factor (TNF) inhibitors, those assigned to tofacitinib (5

2020 Rheumatology Year in Review

Save

2020 was historic, memorable and game-changing. Under the cloud of COVID-19, there were many significant and memorable advances and setbacks for the rheumatology world. In our accounting of most read articles for 2020, (not surprisingly) 17/20 were COVID-related. Below, are our top news items

EULAR Guidance on Patient Adherence to Meds

Save

Non-adherence may be the single most untold risk to suboptimal outcomes in the care of musculoskeletal disease.  It has been estimated that 30-80% of patients with rheumatic and musculoskeletal diseases (RMDs) are nonadherent to prescribed regimens.  EULAR has commissioned a task force to